Growth Metrics

Cannabis Bioscience International Holdings (CBIH) Cost of Revenue (2022 - 2026)

Cannabis Bioscience International Holdings' Cost of Revenue history spans 5 years, with the latest figure at $3045.0 for Q1 2026.

  • On a quarterly basis, Cost of Revenue fell 84.3% to $3045.0 in Q1 2026 year-over-year; TTM through Feb 2026 was $26233.0, a 42.27% decrease, with the full-year FY2025 number at $40106.0, down 12.05% from a year prior.
  • Cost of Revenue hit $3045.0 in Q1 2026 for Cannabis Bioscience International Holdings, down from $10500.0 in the prior quarter.
  • Over the last five years, Cost of Revenue for CBIH hit a ceiling of $24120.0 in Q1 2023 and a floor of $3045.0 in Q1 2026.
  • Historically, Cost of Revenue has averaged $11043.6 across 5 years, with a median of $9349.0 in 2023.
  • Biggest five-year swings in Cost of Revenue: soared 112.86% in 2023 and later crashed 84.3% in 2026.
  • Tracing CBIH's Cost of Revenue over 5 years: stood at $7090.0 in 2022, then soared by 112.86% to $15092.0 in 2023, then plummeted by 48.3% to $7803.0 in 2024, then skyrocketed by 34.56% to $10500.0 in 2025, then plummeted by 71.0% to $3045.0 in 2026.
  • Business Quant data shows Cost of Revenue for CBIH at $3045.0 in Q1 2026, $10500.0 in Q4 2025, and $8143.0 in Q3 2025.